INTRODUCTION

Postthrombotic syndrome (PTS) is a most common chronic complication of deep vein thrombosis (DVT). PTS develops due to valvular incompetence and persistent obstruction. This syndrome is characterized by pain, swelling, a sensation of heaviness, and cramping in the leg [1]. In severe PTS, leg ulcers may develop. While anticoagulation is effective for preventing thrombus extension and recurrence, many patients develop venous incompetence resulting in PTS [2]. PTS develops in 25% to 50% of proximal DVT patients [3,4], despite the use of anticoagulant therapy [5]. Ten percent of PTS patients have moderate PTS and 3% to 5% have severe PTS at 24 months [2]. For many years,
Prevention of PTS

PTS has been known to be associated with impaired quality of life in DVT patients, and as having an influence on patient morbidity [4,6-8]. Several studies have shown that catheter-directed thrombolysis (CDT) is effective for a significant reduction in the incidence of PTS [9-11]. However, its efficacy is controversial, and recent studies have shown that CDT cannot prevent PTS [12]. CDT is also associated with mortality and bleeding risk [11,13]. Studies of the risk factors of PTS are restricted, and we only know that PTS is more common in patients with a proximal DVT [2], recurrent and ipsilateral DVT [3], and an increased body mass index (BMI) [14-16].

The aim of this study is to evaluate the efficacy of CDT for preventing the development of PTS in patients with lower extremity DVT.

**MATERIALS AND METHODS**

1) Patients

We retrospectively reviewed a patient database in Yeungnam University Medical Center from January 2005 to December 2013. DVT was diagnosed with duplex ultrasonography or computed tomography. Excluding isolated calf vein thrombosis and recurrent DVT, 260 limbs of 228 patients were diagnosed as a proximal DVT for the first time. Among them, 126 patients who had undergone the Villalta scale’s assessment were enrolled in this study, with a total of 139 limbs. PTS was defined as Villalta score ≥5 points [17].

2) Treatment

Regarding treatment, all patients received long-term anticoagulation therapy, except three patients who had high bleeding risk. CDT was performed on 55 (39.6%) of the 139 limbs. Indications of CDT were (1) symptom onset time was less than 2 weeks, (2) imaging studies indicate that venous thrombosis had occurred within the past 14 days, and (3) the patients had no bleeding risk. A self-expandable stent was placed if iliac vein stenosis ≥50% was detected after CDT. Outcomes of CDT were as follows: complete lysis in 70.9% (39/55), incomplete lysis (50.0%-99.0%) in 25.5% (14/55), and no lysis (<50.0%) in 3.6% (2/55). An Iliac vein stent was placed in 50.9% of the patients (28/55).

**Table 1. Patient demographic and clinical data**

| Variable                        | CDT (-) (n=84) | CDT (+) (n=55) | Total (n=139) | P-value |
|--------------------------------|----------------|----------------|---------------|---------|
| Age (y)                        | 63.0           | 58.0           | 62.0          | 0.165c  |
| Male                           | 43 (51.2)      | 28 (50.9)      | 71 (51.1)     | 0.974a  |
| Body mass index (kg/m²)        | 24.8           | 24.7           | 24.7          | 0.808b  |
| Symptom duration (d)           | 4.5            | 3.0            | 4.0           | 0.893c  |
| Symptom duration ≤2 weeks      | 67 (79.8)      | 48 (87.3)      | 115 (82.7)    | 0.252a  |
| Side (left)                    | 54 (64.3)      | 44 (80.0)      | 98 (70.5)     | 0.047a  |
| Risk factors of DVT            |                |                |               |         |
| Malignancy                     | 10 (11.9)      | 4 (7.3)        | 14 (10.1)     | 0.375c  |
| Immobility                     | 28 (33.3)      | 5 (9.1)        | 33 (23.7)     | 0.001a  |
| Surgery                        | 24 (28.6)      | 11 (20.0)      | 35 (25.2)     | 0.255a  |
| Trauma                         | 15 (17.9)      | 6 (10.9)       | 21 (15.1)     | 0.263a  |
| Estrogen                       | 1 (1.2)        | 5 (9.1)        | 6 (4.3)       | 0.036c  |
| Pregnancy                      | 2 (2.4)        | 0 (0)          | 2 (1.4)       | 0.518c  |
| History of DVT                 | 6 (7.1)        | 5 (9.1)        | 11 (7.9)      | 0.753c  |
| Thrombophilia                  | 3 (3.6)        | 5 (9.1)        | 8 (5.8)       | 0.264c  |
| Recur during follow-up         | 6 (7.1)        | 0 (0)          | 6 (4.3)       | 0.081c  |
| Extent of thrombus             |                |                |               |         |
| Ilio-femoral                   | 30 (35.7)      | 11 (20.0)      | 41 (29.5)     | 0.011c  |
| Femoro-popliteal               | 54 (64.3)      | 44 (80.0)      | 98 (70.5)     | 0.277c  |
| Ilio-femoro-popliteal          | 19 (22.6)      | 24 (43.6)      | 43 (30.9)     |         |
| Anticoagulation                | 81 (96.4)      | 55 (100.0)     | 136 (97.8)    |         |
| Villalta score >5              | 11 (13.1)      | 6 (10.9)       | 17 (12.2)     | 0.905c  |

Values are presented as median or number (%). DVT, deep vein thrombosis; CDT, catheter directed thrombolysis. *Chi-square test, †Mann-Whitney U test, ‡Fisher-exact test.
3) Statistical analyses

All data were analyzed using the IBM SPSS Statistics ver. 22.0 software (IBM Co., Armonk, NY, USA). When comparing the differences of modalities between the two treatment groups, we used a chi-squared test and Fisher-exact test. The differences in continuous data were analyzed using Student’s t-test or Mann-Whitney U-test when data were not normally distributed. A binary logistic regression model was used to identify the independent risk factors of development of PTS. Statistical significance was defined as P<0.05.

RESULTS

Patient demographic and clinical data are shown in Table 1. The median age of patients was 62 years old and 50.8% were male. Eighty-three percent of patients was acute DVT, with a symptom duration of ≤2 weeks. Left leg involvement was more common in the CDT group. The number of patients with thrombosis from iliac vein to popliteal vein was also significantly higher in the CDT group than in the non-CDT group (44.0% vs. 23.0%, P=0.009). When risk factors of DVT were compared between the two groups, no significant difference was found in the prevalence of risk factors, except immobility and use of estrogen.

During median follow-up at 83 months (range, 30-136 months), PTS had developed in 12 patients. The prevalence of PTS did not differ between the CDT group and the non-CDT group (10.9% [6/55] vs. 13.1% [11/84], P=0.905).

Univariate analyses did not show any significant risk factors related with development of PTS (Table 2). In the multivariate analysis, high BMI (odds ratio [OR], 1.303; 95% confidence interval [CI], 1.079-1.574; P=0.006) and ilio-femoro-popliteal DVT (OR, 3.666; 95% CI, 1.093-12.296; P=0.035) were independent risk factors of the development of PTS (Table 3).

DISCUSSION

Several risk factors are known for developing PTS. Recent studies show recurrent ipsilateral DVT [3,18,19] and increased BMI [14,15,20] are associated with the development of PTS. Location of the primary DVT [12,21] and residual DVT [22,23] is also another risk factor. Proximal distribution of DVT is reportedly a higher risk of PTS [2,14,16].

In this study, high BMI (OR, 1.303; 95% CI, 1.079-1.574; Table 2. Univariate analysis: risk factors of the development of PTS

| Variable                              | PTS (-) (n=122) | PTS (+) (n=17) | P-value |
|---------------------------------------|-----------------|----------------|---------|
| Age (y)                               | 61.5            | 62.0           | 0.966*  |
| Male                                  | 62 (50.8)       | 9 (52.9)       | 0.502*  |
| Body mass index (kg/m²)               | 24.5            | 25.8           | 0.201*  |
| Symptom duration ≤2 weeks             | 104 (85.2)      | 11 (64.7)      | 0.385*  |
| Side (left)                           | 86 (11)         | 12 (70.6)      | 1.000*  |
| Risk factors of DVT                   |                 |                |         |
| Malignancy                            | 12 (9.8)        | 2 (11.8)       | 1.000*  |
| Immobility                            | 30 (24.6)       | 3 (17.6)       | 1.000*  |
| Surgery                               | 31 (25.4)       | 4 (23.5)       | 1.000*  |
| Trauma                                | 17 (13.9)       | 4 (23.5)       | 0.656*  |
| Estrogen                              | 4 (3.3)         | 2 (11.8)       | 1.000*  |
| History of DVT                        | 10 (8.2)        | 1 (5.9)        | 0.582*  |
| Thrombophilia                         | 7 (5.7)         | 1 (5.9)        | 1.000*  |
| Recur during follow-up                | 6 (4.9)         | 0 (0)          | 1.000*  |
| Extent of thrombus                    |                 |                |         |
| Ilio-femoro-popliteal                 | 35 (28.7)       | 8 (47.1)       | 0.112*  |
| Others                                | 87 (71.3)       | 9 (52.9)       |         |
| Anticoagulation                       | 120 (98.4)      | 16 (94.1)      | 0.328*  |
| Catheter directed thrombolysis        | 49 (40.2)       | 6 (35.3)       | 0.729*  |
| Iliac vein stenting                   | 30 (24.6)       | 1 (5.9)        | 0.195*  |

Values are presented as median or number (%).

PTS, postthrombotic syndrome; DVT, deep vein thrombosis.
*Chi-square test, †Mann-Whitney U test, ‡Fisher-exact test.

Table 3. Multivariate analysis: risk factors of the development of postthrombotic syndrome

| Variable                                                  | Relative risk | 95% confidence interval | P-value |
|-----------------------------------------------------------|---------------|-------------------------|---------|
| Age                                                       | 1.303         | 0.962-1.044             | 0.915   |
| Male                                                      | 0.926         | 0.280-3.066             | 0.900   |
| Body mass index                                           | 1.303         | 1.079-1.574             | 0.006   |
| Left side                                                 | 0.849         | 0.231-3.119             | 0.805   |
| Catheter directed thrombolysis                            | 1.317         | 0.367-4.728             | 0.673   |
| Iliac vein stenting                                       | 0.184         | 0.017-1.983             | 0.163   |
| Symptom duration >2 weeks                                 | 2.934         | 0.816-10.546            | 0.099   |
| Ilio-femoro-popliteal deep vein thrombosis                | 3.666         | 1.093-12.296            | 0.035   |
Prevention of PTS

The pathophysiology of PTS has not been fully determined. PTS develops as a result of venous pressure, which is caused by venous obstruction, valvular incompetence, or both. A venous obstruction is injurious to vein walls as it promotes the inflammatory process [24]. The risk of vessel damage increases as the length of the thrombus is in contact with the vein wall increases [25]. This could be reflected in the result of our study since extensive thrombus burden is a risk factor of PTS. Early elimination of thrombus may preserve valvular function and prevent fibrosis, a sequela of chronic thrombus [26]; hence, CDT has been considered as a treatment for the prevention of PTS. However, we were not able to prove that CDT can prevent PTS. The prevalence of PTS was 10.9% at the CDT group and 13.1% at the non-CDT group (P=0.905). PTS development was not associated with CDT. We were not able to prove that CDT can prevent PTS. The prevalence of PTS was 10.9% at the CDT group and 13.1% at the non-CDT group (P=0.905). PTS development was not associated with CDT.

In the CaVenT trial, 189 patients (90.4% of the 209 patients randomly assigned) had a first time ilio-femoral DVT were included within 21 days from the symptom onset who were included in the CDT group and control group [9,10]. The development of PTS in the CDT group had an absolute risk reduction of 14.4% after 2 years and 28.0% after 5 years of follow-up compared with standard treatment. The long-term beneficial effect of preventing PTS in CDT increased with time.

The Cochrane Library reported that the thrombolysis group showed improvement in venous patency. The review enrolled 17 controlled trials that randomized a total of 1,103 people. At up to five years after follow-up, the thrombolysis group was reported to have significantly less PTS (relative risk [RR], 0.66; 95% CI, 0.53-0.81; P<0.0001), but those receiving thrombolysis had increased bleeding complications (RR, 2.23; 95% CI, 0.41-3.52; P<0.0006) [11].

In the recent Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) study, in which 692 patients were enrolled from 56 clinical centers in the United States, the addition of pharmacomechanical CDT to anticoagulation did not show any reduction in the risk of the PTS over a follow-up of 2 years (47.0% in the pharmacomechanical-thrombolysis group and 48.0% in the control group; RR, 0.96; 95% CI, 0.82-1.11; P=0.560). The addition of pharmacomechanical CDT to anticoagulation resulted in a higher risk of major bleeding [12]. The size of the ATTRACT study was larger than that of the catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (CaVenT) study (692 patients vs. 209 patients, respectively). In addition, in the CaVenT study, a conventional catheter was used, while pharmacomechanical thrombolysis was used in the ATTRACT trial.

According to the result of the ATTRACT study, a metaanalysis was performed on 6 comparative studies and 4 randomized controlled trials including the ATTRACT trial and the CaVenT study [27]. That meta-analysis showed that pharmacomechanical thrombolysis improved the patency or the severity of the ilio-femoral vein (95% CI, 2.36-4.67; I²=44.0%, P<0.00001) and reduced the risk of PTS (95% CI, 0.51-0.82; I²=78.0%, P=0.0002) compared with anticoagulation therapy alone; however, CDT was not shown to prevent mild PTS (95% CI, 0.74-1.39; I²=79.0%, P=0.410) in the subgroup analysis of randomized controlled trials, CDT was not shown to prevent PTS (95% CI, 0.65-1.10; I²=59.0%, P=0.200). There was also a statistically significant increase in bleeding complication in this study (95% CI, 1.91-3.04; I²=33.0%, P<0.00001).

Based on previous studies, it is difficult to conclude that CDT can help prevent PTS and it is still controversial. Although this study has some limitations, such as retrospective design and relatively small sample size, it was shown that PTS could not reduce PTS development.

In conclusion, we suggest that a higher BMI and longer thrombotic burden are associated with the development of PTS in patients with DVT and that CDT is not effective in preventing PTS.

REFERENCES

1) Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognosis and need for progress. Br J Haematol 2009;145:286-295.
2) Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, et al. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008;149:698-707.
3) Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
4) Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002;162:1144-1148.
5) Kahn SR. The post-thrombotic syndrome: progress and pitfalls. Br J Haematol 2006;134:357-365.
6) Guanella R, Ducruet T, Johri M, Miron

https://doi.org/10.5758/vsi.2018.34.2.26

29
MJ, Roussin A, Desmarais S, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost 2011;9:2397-2405.

7) Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008;28:370-372.

8) Kahn SR, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005;165:1173-1178.

9) Haig Y, Enden T, Grettas O, Kløw NE, Slagsvold CE, Ghanima W, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol 2016; 3:e64-e71.

10) Enden T, Haig Y, Kløw NE, Slagsvold CE, Sandvik L, Ghanima W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012;379:31-38.

11) Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2014 : 23(1) : CD002783.

12) Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017;377:2240-2252.

13) Bashir R, Zack CJ, Zhao H, Comerota AJ, Bove AA. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs. anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med 2014;174:1494-1501.

14) Stain M, Schönauer V, Minar E, Bialonczyk C, Hirschl M, Weltermann A, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 2005;3:2671-2676.

15) Ageno W, Piantanida E, Dentali F, Steidl L, Mera V, Squizzato A, et al. Body mass index is associated with the development of the post-thrombotic syndrome. Thromb Haemost 2003; 89:305-309.

16) Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost 2008;6:2075-2081.

17) Soosainathan A, Moore HM, Gohel MS, Davies AH. Scoring systems for the post-thrombotic syndrome. J Vasc Surg 2013;57:254-261.

18) Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004;141: 249-256.

19) Labropoulos N, Gasparis AP, Tassopoulos AK. Prospective evaluation of the clinical deterioration in post-thrombotic limbs. J Vasc Surg 2009; 50:826-830.

20) Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost 2008;6:2075-2081.

21) Schulman S, Granqvist S, Juhlin-Danulf A, Lockner D. Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase. Acta Med Scand 1986;219:349-357.

22) Piovella F, Crippa L, Barone M, Viganò D’Angelo S, Serafini S, Galli L, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002;87:515-522.

23) Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-960.

24) Henke PK, Varma MR, Moaveni DK, Dewyer NA, Moore AJ, Lynch EM, et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. Thromb Haemost 2007;98:1045-1055.

25) Henke PK, Comerota AJ. An update on etiology, prevention, and therapy of postthrombotic syndrome. J Vasc Surg 2011;53:500-509.

26) Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness DE Jr. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg 1993;18:606-608. doi:10.1177/1076029617739703.